Endoglin is a nonsignaling receptor for transforming growth factor that contributes to the action of this growth factor in diverse cell types. It may also exhibit a function of its own. Endoglin levels vary with disease states and is a marker of new blood vessels. We studied endoglin expression in whole-mount prostate sections from 64 patients with localized prostate cancer, assessing reactivity in the epithelium, the stroma, and blood vessels. Cells in normal/benign acini were negative but significantly immunoreactive (Po0.001) in both prostatic intraepithelial neoplasia (PIN; 52% of cases) and malignant areas (77% of cases). In tumors, this involved less than 25% of malignant cells in 59% of specimens. The endoglin-stained stroma was detected mainly in areas surrounding PIN acini and tumors. Endoglin antibodies detected more microvessels than von Willebrand Factor antibodies in all prostatic areas (Po0.01). In addition, the number of microvessels increased with the development of cancer and correlated with Gleason score (Po0.01). Changes in endoglin expression in PIN and malignant cells, the surrounding stroma, and related blood vessels, suggest that endoglin function may be altered in prostate cancer.
Introduction
Endoglin or CD105 is a 180-kDa disulfide-linked homodimeric transmembrane glycoprotein that specifically binds TGF-b 1 and TGF-b 3 with high affinity at the cell surface. 1, 2 In the membrane, endoglin forms heteromeric complexes with type I and type II TGF-b receptors that are responsible of transducing TGF-b signals through their intrinsic serine/threonine kinase activity. 3 Betaglycan, another nonsignaling TGF-b receptor, is occasionally found in TGF-b signaling complexes together with endoglin. 4 The contribution of endoglin to TGF-b signaling and action on cells was demonstrated in diverse systems using strategies such as antisense and neutralizing endoglin antibodies. [5] [6] [7] Endoglin is critical in angiogenesis and early development as mice lacking endoglin show vascular and heart defects. 8 Moreover, mutations in the endoglin gene (mapping at 9q33-q34) result in anomalies of blood vessels, as seen in human hereditary hemorrhagic telangiectasia type I. 9, 10 The endoglin expression profile in organs and tissues indicates that this protein, often referred to as a proliferation-associated antigen of angiogenesis, is primarily a marker of endothelial cells expressed at particularly elevated levels in angiogenic areas such as in the placenta, tissue regeneration after injury, and tumor growth, including prostate cancer. 5, [11] [12] [13] Besides blood vessels, endoglin expression was reported in diverse stromal and inflammatory cells, with fluctuating levels according to cell activation status or growth patterns. Examples are trophoblasts, 5 stromal uterine cells, 6 mesenchymal stem cells and hemopoietic precursor cells of the bone marrow, 14 and myeloid elements in rheumatoid synovial tissues. 15 On the other hand, endoglin is rarely detected in normal epitheliums, with the exception of the glomerular mesangium in human kidneys 16 and melanocytes. 17 Of particular interest is that in addition to leukemic cells, 1 endoglin is expressed in cancers, namely melanoma 17 and ovarian carcinoma. 18 Altogether endoglin expression levels in blood vessels but also in stromal and to some extent epithelial cells, seem to be altered according to diseases in diverse human tissues. Notably, endoglin expression has been reported in immortalized human prostate cells and prostate cancer cell lines and modifications in endoglin levels resulted in altered cell adhesion and migration/invasion. 19, 20 Based on these findings and possible changes in the composition of TGF-b receptor complexes and hence tumor cell sensitivity to TGF-b in prostate cancer, 21 the objectives of this study were to test in whole-mount sections of human prostate: (1) whether endoglin protein expression in the stroma and epithelium differs with the onset of proliferative diseases and (2) whether assessment of blood vessels is similar between endoglin and von Willebrand Factor (vWF).
Materials and methods

Tissues
Prostates were obtained from 64 patients (average age 61. 875.9 y) who underwent radical prostatectomy for localized prostate cancer. Benign, PIN, and cancer areas were mapped in all tissue sections by a dedicated boardcertified GU-pathologist, Dr Louis R Bégin (Sacré-Coeur Hospital, Montréal, Que., Canada). Tissue sections with the highest tumor burden were chosen for analysis. Patient characteristics are depicted in Table 1 . Notably, 52 patients had moderately differentiated cancer with pathological Gleason score of 5-7, while 12 patients showed a poorly differentiated cancer with a Gleason score of 8-10.
Immunohistochemistry
All steps were performed at room temperature. The prostate was immediately fixed in formalin overnight and totally submitted for paraffin embedding and wholemount sectioning. For staining, sections (4 mm) were deparaffinized with toluene and rehydrated through graded ethanol. Following each step, sections were washed with 0.01 M TTBS (Tween/Tris-buffered saline solution) for 10 min. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide/50% methanol for 15 min. Endoglin expression was studied using monoclonal SN6h antibodies (obtained from Dako Corp., Ont., Canada), also shown to detect specifically endoglin by Western blotting using extracts from human microvascular endothelial cells. 4 The immunostaining protocol was first optimized by testing different concentrations of antibodies (from 1 : 200 to 1 : 5000), with or without amplification system (Dako Corp.), after blocking nonspecific binding sites using 10% normal goat serum (30 min). Optimal endoglin staining with minimal background was obtained at 1 : 1000 dilution of antibody in 0.01 M TTBS for 1 h. Serial sections were next incubated successively with endoglin antibodies and complexes were revealed using a biotinconjugated anti-mouse secondary antibody (1 h), followed by streptavidin-peroxidase conjugate (Zymed, San Francisco, CA, USA), and finally the chromogenic substrate solution (0.006% 3,3 0 -diaminobenzidine tetrahydrochloride/0.01% hydrogen peroxide in TBS).
Blood vessels were stained on consecutive tissue sections using rabbit polyclonal vWF antibodies (1 : 800 dilution, 1 h; Dako Corp.), according to the manufacturer's instructions. An antigen retrieval technique consisting in a 15-min digestion with 0.1% pronase (Boehringer Mannheim, Germany) in TBS (Tween free) was first applied and followed by incubation with 10% normal goat serum. Other steps were essentially similar and performed using the Histostain-SP Bulk kit (Zymed). Primary antibodies were omitted in negative controls. Sections were counterstained with Mayer's hematoxylin and mounted.
Evaluation of staining and quantification of blood vessels
Every whole-mount section was examined by light microscopy and evaluated by two independent observers (WK and HRI) for frequency and intensity of endoglin epithelial, stromal, and endothelial staining in normal and/or benign areas (far from cancer), PIN, and cancer regions. Regions containing severe inflammation were excluded. Both observers were responsible for scoring and the interobserver coefficient of variance for endoglin and vWF was in the range of 3.0-4.8%, respectively. The intensity of endoglin staining was evaluated semiquantitatively on a scale ranging from 0 to 5 þ . Stained blood vessels were counted in five Â 100 magnified fields for each region. Means and medians were calculated and 
Results
Endoglin staining in epithelial and stromal compartments
Endoglin antibodies specifically stained prostatic epithelial cells and the stroma. Results on the reactivity of epithelial cells are summarized in Tables 2 and 3 . Overall, there was no endoglin expression in normal/ benign glands of 91% of cases with the exception of six cases exhibiting varying degrees of staining. However, significant staining was detected in approximately 25% of PIN areas in 52% (33/64) of cases ( Table 2 ). An example of immunoreactivity in PIN lesions with intense endoglin staining is shown in Figure 1a . Staining was always cytoplasmic and speckled. Cancer cells were also stained (see Figure 1c ) and endoglin was observed in 77% (49/64) of cases (Table 2 ). When both PIN and cancer cells were immunoreactive within a section, the staining intensity on a cellular basis was often more intense in PIN than in cancer, with an average in the 3-5 þ range for PIN vs 3 þ for cancer cells. The difference of endoglin immunoreactivity in cancer (77% of cases) and PIN acini (52%) vs benign glands (9%) was significant (Po 0.001). When the extent of endoglin staining in tumors was evaluated in the 49 positive cases (Table 3) , reactivity was seen in less than 25% of cancer cells in a majority of whole-mount prostates (59%) but extended to more than 75% of cancer cells in 12.5% of specimens. The endoglin immunoreactivity in cancer cells did not correlate with serum levels of PSA and/or PSA density (P40.05), Gleason score (P ¼ 0.30), stage (P ¼ 0.67), and extracapsular extension or seminal vesicles involvement (P ¼ 0.73 and 0.80, respectively). Endoglin antibodies also significantly reacted with the stroma differentially according to disease, with an immunoreactivity surrounding benign, PIN, and cancerous glands in 32, 76, and 92% of cases, respectively (P ¼ 0.002). Figure 1 shows the endoglin-positive stroma, surrounding negatively (b, d) or positively (c) stained epithelial cells in PIN and tumors. The converse (negative stroma around positive epithelial/tumor cells) is seen in Figure 1a . No significant correlation was obtained between stromal endoglin in tumors and PSA, PSA density, as well as other patient/tumor characteristics (P equal or higher than 0.1).
Endoglin and vWF staining in blood vessels
Endoglin-and vWF-stained blood vessels were seen in all regions (benign, PIN, and cancer) of whole-mount sections. Examples of endoglin-stained microvessels in different regions of the prostate and of consecutive sections stained with both endoglin vs vWF antibodies are shown in Figure 1 (e-h). The number of blood vessels significantly increased from benign to PIN to cancer areas with both markers (Table 4 ; Po 0.01), but endoglin antibodies detected a greater number of microvessels. Differences between the two markers were significant in all regions (Po0.01) and superior in cancer. Moreover, the endoglin staining intensity in endothelial cells was greater in cancer and PIN than in benign areas (60 vs 4% demonstrated 3-4 þ intensity). Table 5 indicates that the number of endoglin-stained tumor blood vessels was not associated with age (P ¼ 0.90), preprostatectomy serum PSA (P ¼ 0.80) and PSA density (P40.05), clinical stage (P ¼ 0.90), extracapsular extension (P ¼ 0.98) and seminal vesicles involvement (P ¼ 0.29). A significant correlation was observed with Gleason score (P ¼ 0.002) and biological (PSA) recurrence (P ¼ 0.02, at a cutoff number of endoglin-stained microvessels of 102). The number of vWF-stained tumor blood vessels was also associated with Gleason score (P ¼ 0.01).
Discussion
The present study on whole-mount sections depicts for the first time endoglin expression in the epithelial and stromal compartments of the human prostate and confirms endoglin as a marker of the endothelium in this tissue, as recently reported using trans-urethral resections (TUR). 13 Other novel observations are that premalignant (PIN) and malignant (cancer) lesions of the prostate are accompanied by an upregulation of endoglin in the stromal and epithelial compartments as well as in endothelial cells of blood vessels, also preferentially stained using endoglin vs vWF antibodies. Moreover, tumor-associated endoglin-stained blood vessels correlated with Gleason score and biological recurrence. Thus, endoglin appears to be a highly sensitive angiogenic marker in several malignancies. 13, [22] [23] [24] 31 Several factors may be invoked to explain the endoglin staining pattern seen in the present study and not reported in TUR specimens. While this includes tissue processing, methodology, and analysis of different areas (normal/benign, PIN and cancer), the types of surgical specimens (whole-mount vs TUR) is likely in cause. For instance, endoglin staining in the stroma around negative-PIN acini and tumors in a small size specimen may be interpreted as non specific. This may similarly apply to tumor cell endoglin staining since in whole-mount sections, less than 25% of cancer cells were immunoreactive in 59% of specimens. On the other hand, the observed changes (extent and intensity of staining) in stromal and epithelial/tumor endoglin levels were significant and correlated with the development of the disease. Indeed, and although truly 'normal' prostates from young men (autopsy, organ donors) could not be processed as whole-mounts in our setting, the lack of staining in the normal/benign epithelium in the studied patient's population (91% of cases) is in agreement with the literature. 12, [14] [15] [16] [17] [18] On the other hand, observations on high endoglin-staining in epithelial cells of PIN lesions and tumors in these whole-mount sections, and often more intense in PIN than cancer within a specimen, are 20 While this may suggest a link with early phases of the disease, studies are underway to establish whether endoglin expression in prostate tumor cells is associated progression. Notably, in vitro studies in prostatic carcinoma cell lines indicate that endoglin exerts a function of its own linked to adhesion and migration/invasion. 20 To date, prostatic microvessels were quantified using several markers (vWF, CD31, CD34). [25] [26] [27] [28] [29] [30] For instances, vWF and/or CD34 staining indicates an intratumoral blood vessel density about 2-fold greater than in adjacent normal/benign areas. 27, 28 Such a conclusion on significantly increased number of microvessels from normal/ benign to PIN to cancer areas was also reached in the present study using vWF and endoglin as markers. While values for vWF-stained microvessels were within the reported range for a similar group of patients, 25 significant differences between the two markers were observed when comparing consecutive sections. Indeed, endoglin antibodies stained at least 1.7-2.6 times more blood vessels than vWF antibodies and the endoglin staining intensity per endothelial cell was significantly higher in PIN and cancer. Such as superiority of endoglin over vWF but also CD31 and CD34 was reported in other tumors. 22, 23, 31 In TUR specimens, there was approximately 4-fold lower number of endoglin-vs vWF-stained tumor vessels. 13 Whether this discrepancy is due to differences in methods, cases, and use of whole mount vs TUR sections is unknown, but in both series, endoglinstained tumor microvessels (and vWF in the present series) correlated with Gleason score. Conflicting data were reported with other markers. 25, 26, [28] [29] [30] Given the requirement of endoglin for the formation of new blood vessels and its expression pattern in activated endotheliums and cycling vs noncycling cells, 5, [8] [9] [10] [11] [12] it is conceivable that endothelial cells expressing this proliferation-associated antigen reflect microvessels at different stages of their formation. Based on the present prostate cancer patient population, it appears that angiogenesis (endoglin-stained blood vessels) occurs in all areas of the prostate but at a much higher extent in malignant lesions. The significant correlation between these newly formed blood vessels and biological recurrence supports the prognostic value of endoglin as an angiogenic marker in prostate tumors. This is consistent with the study in TURP samples showing a relationship with TGF-b tumor cell immunoreactivity. 13 Thus changes in endoglin expression in prostatic microvessels likely reflect differences in the composition of TGF-b receptor complexes at the endothelial cell surface during their formation and hence, a window for the contribution of TGF-b in the angiogenic process.
Conclusion
We report the first study on progressive changes in endoglin expression in the epithelial and stromal compartments of the prostate with the development of PIN and cancer and confirm endoglin expression in blood vessels. Moreover, endoglin is a more sensitive angiogenic marker than the pan-endothelial marker, vWF, in the prostate and correlates with Gleason score and biological recurrence. 
